Tobira Therapeutics, Inc. (Tobira) is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to treat liver disease, human immunodeficiency virus (HIV) fibrosis and inflammation. The Company�s product candidate, cenicriviroc (CVC,) is an immunomodulator that can be used to treat a number of disease states with high unmet medical need. CVC has been evaluated in a total of 16 completed Phase 1 and Phase 2 clinical trials in approximately 550 healthy volunteers and patients with HIV-1. The Company is developing CVC for non-alcoholic steatohepatitis (NASH). CVC is an oral, long-acting, once-daily, potent dual inhibitor, or antagonist, of chemokine receptor type 2 (CCR2), and type 5 (CCR5), with anti-inflammatory and anti-fibrotic activity. NASH is a severe type of non-alcoholic fatty liver disease (NAFLD).